<p>Biohaven Ltd.（纽约证券交易所代码：BHVN - 获取免费报告）周一交易中股价上涨了 8.8%。该股票最高交易价为 10.25 美元，最后交易价为 10.39 美元。在午盘交易中，约有 1,143,064 股交易，较日均交易量 2,260,137 股下降了 49%。该股票此前收盘价为 9.55 美元。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>Biohaven 内部人士押注 3300 万美元于公司复苏</li>
</ul>
<p>BHVN 近期成为多份分析师报告的主题。BTIG Research 在 11 月 18 日的研究报告中重申了对 Biohaven 的 “买入” 评级，并给出了 16.00 美元的目标价。Cowen 在 11 月 5 日的研究报告中重申了对 Biohaven 的 “买入” 评级。摩根士丹利在 11 月 18 日的研究报告中将 Biohaven 的目标价从 54.00 美元下调至 26.00 美元，并对该股票设定了 “增持” 评级。美国银行在 11 月 5 日的报告中将 Biohaven 的评级从 “买入” 下调至 “中性”，并设定了 10.00 美元的目标价。最后，Raymond James Financial 在 11 月 5 日的研究报告中重申了对 Biohaven 的 “强力买入” 评级。两位投资分析师给予该股票 “强力买入” 评级，九位给予 “买入” 评级，六位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 25.93 美元。</p>
<p><strong>查看我们关于 Biohaven 的最新报告</strong></p>
<h2>Biohaven 股价上涨 11.2%</h2>
<ul>
<li>Biohaven 股票因药物试验结果飙升：现在是入场的时机吗？</li>
</ul>
<p>该公司的债务与股本比率为 1.91，速动比率为 2.86，流动比率为 2.86。该公司的 50 日移动平均价为 12.89 美元，200 日移动平均价为 14.11 美元。该公司的市值为 11.2 亿美元，市盈率为-1.40，贝塔值为 1.14。</p>
<p>Biohaven（纽约证券交易所代码：BHVN - 获取免费报告）最近一次公布季度财报是在 11 月 10 日。该公司报告每股收益（EPS）为-1.64 美元，超出分析师的共识预期-1.91 美元，超出幅度为 0.27 美元。平均而言，股票研究分析师预计 Biohaven Ltd.在当前财政年度将发布-8.9 的每股收益。</p>
<h2>Biohaven 内部活动</h2>
<p>在相关消息中，首席执行官 Vlad Coric 于 11 月 13 日的交易中购买了 666,666 股 Biohaven 股票。每股平均成本为 7.50 美元，总交易额为 4,999,995.00 美元。完成购买后，首席执行官在公司持有 1,195,275 股，估值约为 8,964,562.50 美元。此次交易使其持股增加了 126.12%。该交易已在与证券交易委员会的法律文件中披露，您可以通过此链接访问。此外，首席会计官 George C. Clark 于 11 月 17 日的交易中购买了 17,000 股该股票。该股票的平均购买价格为 8.52 美元，总价值为 144,840.00 美元。收购后，首席会计官在公司持有 20,000 股，估值约为 170,400 美元。这代表其持股增加了 566.67%。该购买的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士购买了价值 33,144,833 美元的 4,416,999 股公司股票。公司内部人士持有公司股票的 14.60%。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近增加或减少了对该公司的持股。US Bancorp DE 在第一季度将其在 Biohaven 的持股增加了 62.8%。US Bancorp DE 现在持有 4,837 股公司股票，价值 116,000 美元，此前在上个季度购买了 1,866 股。PNC 金融服务集团在第一季度将其在 Biohaven 的持股增加了 53.7%。PNC 金融服务集团现在持有 1,783 股公司股票，价值 43,000 美元，此前在上个季度购买了 623 股。瑞士国家银行在第一季度将其在 Biohaven 的持股增加了 7.6%。瑞士国家银行现在持有 166,500 股公司股票，价值 4,003,000 美元，此前在上个季度购买了 11,700 股。Invesco Ltd.在第一季度将其在 Biohaven 的持股增加了 32.1%。Invesco Ltd.现在持有 68,460 股公司股票，价值 1,646,000 美元，此前在上个季度购买了 16,646 股。最后，凯通国际资产管理有限公司在第一季度将其在 Biohaven 的持股增加了 181,971.4%。凯通国际资产管理有限公司现在持有 12,745 股公司股票，价值 306,000 美元，此前在上个季度购买了 12,738 股。机构投资者和对冲基金持有公司股票的 88.78%。</p>
<h2>Biohaven 公司简介</h2>
<p>（获取免费报告）</p>
<p>Biohaven Ltd.及其子公司专注于全球范围内发现、开发和商业化免疫学、神经科学和肿瘤学的疗法。该公司的产品管线包括 Troriluzole，目前正在进行针对神经和精神疾病的第三阶段临床试验；BHV-5500，阻断由突触后 NMDA 受体介导的谷氨酸信号传导；Taldefgrobep Alfa，目前正在进行针对脊髓性肌萎缩症和肥胖症的第三阶段临床试验；BHV-7000，正在进行针对局灶性和全身性癫痫、双相情感障碍和重度抑郁症的第二/第三阶段临床试验的候选药物；BHV-2100，正在进行针对偏头痛和神经性疼痛的第一阶段临床试验；以及 BHV-8000，正在进行针对早期阿尔茨海默病和帕金森病、硬化症和淀粉样蛋白相关影像异常的第一阶段临床试验的产品候选药物。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Biohaven</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>5 只内部人士正在抛售的科技股（但聪明的投资者正在大量买入）</li>
<li>什么是特别股息？</li>
<li>为什么 FuelCell Energy 股票在政府达成协议后飙升</li>
<li>什么是 WallStreetBets，他们正在关注哪些股票？</li>
<li>软银的下一个 AI 动作？DigitalBridge 因收购传闻上涨 46%</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Biohaven 吗？</h2>
<p>在考虑 Biohaven 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Biohaven 并不在名单上。</p>
<p>虽然 Biohaven 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Biohaven药业

<p>Biohaven Ltd.（纽约证券交易所代码：BHVN）股价上涨 8.8%，至 10.39 美元，受到内部人士买入活动和分析师评级不一的影响。首席执行官 Vlad Coric 购买了 666,666 股，增持幅度达到 126.12%。分析师的评级各不相同，普遍目标价为 25.93 美元。机构投资者已调整其持仓，内部人士持股比例达到 14.60%。尽管分析师意见不一，但该股近期的表现和内部活动表明可能存在投资兴趣</p>

<p>Shares of Biohaven Ltd. (NYSE:BHVN - Get Free Report) rose 8.8% during trading on Monday . The stock traded as high as $10.25 and last traded at $10.39. Approximately 1,143,064 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 2,260,137 shares. The stock had previously closed at $9.55.</p>
<div class="lb-trans"><p>Biohaven Ltd.（纽约证券交易所代码：BHVN - 获取免费报告）周一交易中股价上涨了 8.8%。该股票最高交易价为 10.25 美元，最后交易价为 10.39 美元。在午盘交易中，约有 1,143,064 股交易，较日均交易量 2,260,137 股下降了 49%。该股票此前收盘价为 9.55 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Biohaven Insiders Bet $33 Million on a Turnaround</li>
</ul>
<div class="lb-trans"><ul>
<li>Biohaven 内部人士押注 3300 万美元于公司复苏</li>
</ul>
</div><p>BHVN has been the topic of a number of recent analyst reports. BTIG Research reissued a &#34;buy&#34; rating and issued a $16.00 price objective on shares of Biohaven in a research note on Tuesday, November 18th. Cowen restated a &#34;buy&#34; rating on shares of Biohaven in a research note on Wednesday, November 5th. Morgan Stanley decreased their price target on Biohaven from $54.00 to $26.00 and set an &#34;overweight&#34; rating on the stock in a research note on Tuesday, November 18th. Bank of America lowered shares of Biohaven from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $10.00 target price on the stock. in a report on Wednesday, November 5th. Finally, Raymond James Financial reissued a &#34;strong-buy&#34; rating on shares of Biohaven in a research report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $25.93.</p>
<div class="lb-trans"><p>BHVN 近期成为多份分析师报告的主题。BTIG Research 在 11 月 18 日的研究报告中重申了对 Biohaven 的 “买入” 评级，并给出了 16.00 美元的目标价。Cowen 在 11 月 5 日的研究报告中重申了对 Biohaven 的 “买入” 评级。摩根士丹利在 11 月 18 日的研究报告中将 Biohaven 的目标价从 54.00 美元下调至 26.00 美元，并对该股票设定了 “增持” 评级。美国银行在 11 月 5 日的报告中将 Biohaven 的评级从 “买入” 下调至 “中性”，并设定了 10.00 美元的目标价。最后，Raymond James Financial 在 11 月 5 日的研究报告中重申了对 Biohaven 的 “强力买入” 评级。两位投资分析师给予该股票 “强力买入” 评级，九位给予 “买入” 评级，六位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 25.93 美元。</p>
</div><p><strong>Check Out Our Latest Report on Biohaven</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Biohaven 的最新报告</strong></p>
</div><h2>Biohaven Trading Up 11.2%</h2>
<div class="lb-trans"><h2>Biohaven 股价上涨 11.2%</h2>
</div><ul>
<li>Biohaven Stock Soars on Drug Trial Results: Time to Jump In?</li>
</ul>
<div class="lb-trans"><ul>
<li>Biohaven 股票因药物试验结果飙升：现在是入场的时机吗？</li>
</ul>
</div><p>The company has a debt-to-equity ratio of 1.91, a quick ratio of 2.86 and a current ratio of 2.86. The firm has a 50-day moving average of $12.89 and a 200-day moving average of $14.11. The firm has a market capitalization of $1.12 billion, a P/E ratio of -1.40 and a beta of 1.14.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 1.91，速动比率为 2.86，流动比率为 2.86。该公司的 50 日移动平均价为 12.89 美元，200 日移动平均价为 14.11 美元。该公司的市值为 11.2 亿美元，市盈率为-1.40，贝塔值为 1.14。</p>
</div><p>Biohaven (NYSE:BHVN - Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.91) by $0.27. On average, equities research analysts anticipate that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Biohaven（纽约证券交易所代码：BHVN - 获取免费报告）最近一次公布季度财报是在 11 月 10 日。该公司报告每股收益（EPS）为-1.64 美元，超出分析师的共识预期-1.91 美元，超出幅度为 0.27 美元。平均而言，股票研究分析师预计 Biohaven Ltd.在当前财政年度将发布-8.9 的每股收益。</p>
</div><h2>Insider Activity at Biohaven</h2>
<div class="lb-trans"><h2>Biohaven 内部活动</h2>
</div><p>In related news, CEO Vlad Coric acquired 666,666 shares of Biohaven stock in a transaction dated Thursday, November 13th. The shares were acquired at an average cost of $7.50 per share, for a total transaction of $4,999,995.00. Following the completion of the purchase, the chief executive officer owned 1,195,275 shares in the company, valued at approximately $8,964,562.50. The trade was a 126.12% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CAO George C. Clark bought 17,000 shares of the stock in a transaction dated Monday, November 17th. The stock was bought at an average price of $8.52 per share, with a total value of $144,840.00. Following the acquisition, the chief accounting officer owned 20,000 shares in the company, valued at approximately $170,400. This represents a 566.67% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders bought 4,416,999 shares of company stock worth $33,144,833. Company insiders own 14.60% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Vlad Coric 于 11 月 13 日的交易中购买了 666,666 股 Biohaven 股票。每股平均成本为 7.50 美元，总交易额为 4,999,995.00 美元。完成购买后，首席执行官在公司持有 1,195,275 股，估值约为 8,964,562.50 美元。此次交易使其持股增加了 126.12%。该交易已在与证券交易委员会的法律文件中披露，您可以通过此链接访问。此外，首席会计官 George C. Clark 于 11 月 17 日的交易中购买了 17,000 股该股票。该股票的平均购买价格为 8.52 美元，总价值为 144,840.00 美元。收购后，首席会计官在公司持有 20,000 股，估值约为 170,400 美元。这代表其持股增加了 566.67%。该购买的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士购买了价值 33,144,833 美元的 4,416,999 股公司股票。公司内部人士持有公司股票的 14.60%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. US Bancorp DE increased its position in Biohaven by 62.8% during the first quarter. US Bancorp DE now owns 4,837 shares of the company's stock worth $116,000 after buying an additional 1,866 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Biohaven by 53.7% during the first quarter. PNC Financial Services Group Inc. now owns 1,783 shares of the company's stock worth $43,000 after purchasing an additional 623 shares during the last quarter. Swiss National Bank lifted its holdings in Biohaven by 7.6% during the 1st quarter. Swiss National Bank now owns 166,500 shares of the company's stock worth $4,003,000 after buying an additional 11,700 shares in the last quarter. Invesco Ltd. raised its holdings in Biohaven by 32.1% during the 1st quarter. Invesco Ltd. now owns 68,460 shares of the company's stock worth $1,646,000 after purchasing an additional 16,646 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Biohaven by 181,971.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 12,745 shares of the company's stock worth $306,000 after buying an additional 12,738 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该公司的持股。US Bancorp DE 在第一季度将其在 Biohaven 的持股增加了 62.8%。US Bancorp DE 现在持有 4,837 股公司股票，价值 116,000 美元，此前在上个季度购买了 1,866 股。PNC 金融服务集团在第一季度将其在 Biohaven 的持股增加了 53.7%。PNC 金融服务集团现在持有 1,783 股公司股票，价值 43,000 美元，此前在上个季度购买了 623 股。瑞士国家银行在第一季度将其在 Biohaven 的持股增加了 7.6%。瑞士国家银行现在持有 166,500 股公司股票，价值 4,003,000 美元，此前在上个季度购买了 11,700 股。Invesco Ltd.在第一季度将其在 Biohaven 的持股增加了 32.1%。Invesco Ltd.现在持有 68,460 股公司股票，价值 1,646,000 美元，此前在上个季度购买了 16,646 股。最后，凯通国际资产管理有限公司在第一季度将其在 Biohaven 的持股增加了 181,971.4%。凯通国际资产管理有限公司现在持有 12,745 股公司股票，价值 306,000 美元，此前在上个季度购买了 12,738 股。机构投资者和对冲基金持有公司股票的 88.78%。</p>
</div><h2>Biohaven Company Profile</h2>
<div class="lb-trans"><h2>Biohaven 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.</p>
<div class="lb-trans"><p>Biohaven Ltd.及其子公司专注于全球范围内发现、开发和商业化免疫学、神经科学和肿瘤学的疗法。该公司的产品管线包括 Troriluzole，目前正在进行针对神经和精神疾病的第三阶段临床试验；BHV-5500，阻断由突触后 NMDA 受体介导的谷氨酸信号传导；Taldefgrobep Alfa，目前正在进行针对脊髓性肌萎缩症和肥胖症的第三阶段临床试验；BHV-7000，正在进行针对局灶性和全身性癫痫、双相情感障碍和重度抑郁症的第二/第三阶段临床试验的候选药物；BHV-2100，正在进行针对偏头痛和神经性疼痛的第一阶段临床试验；以及 BHV-8000，正在进行针对早期阿尔茨海默病和帕金森病、硬化症和淀粉样蛋白相关影像异常的第一阶段临床试验的产品候选药物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Biohaven</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>5 Tech Stocks Insiders Are Selling (But Smart Investors Are Loading Up)</li>
<li>What is a Special Dividend?</li>
<li>Why FuelCell Energy Stock Is Soaring After a Government Deal</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>SoftBank’s Next AI Move? DigitalBridge Rockets 46% on Takeover Buzz</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Biohaven</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>5 只内部人士正在抛售的科技股（但聪明的投资者正在大量买入）</li>
<li>什么是特别股息？</li>
<li>为什么 FuelCell Energy 股票在政府达成协议后飙升</li>
<li>什么是 WallStreetBets，他们正在关注哪些股票？</li>
<li>软银的下一个 AI 动作？DigitalBridge 因收购传闻上涨 46%</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Biohaven Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Biohaven 吗？</h2>
</div><p>Before you consider Biohaven, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Biohaven 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Biohaven 并不在名单上。</p>
</div><p>While Biohaven currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Biohaven 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Biohaven（NYSE:BHVN）股价上涨 8.8% - 仍然值得买入吗？